Simple Summary Prostate cancer is the most common tumor in men. Although there have
been many new developments in the last few years, metastatic castration resistant prostate …

The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a
pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of …

Background In a phase 2 study, rucaparib, an inhibitor of poly (ADP-ribose) polymerase
(PARP), showed a high level of activity in patients who had metastatic, castration-resistant …

Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …

Abstract Background Initial TRITON2 (NCT02952534) results demonstrated the efficacy of
rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer …

PURPOSE ARTO (ClinicalTrials. gov identifier: NCT03449719) is a multicenter, phase II
randomized clinical trial testing the benefit of adding stereotactic body radiation therapy …

Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease.
However, in recent years, several treatments have been shown to improve the outcome of …

Simple Summary Recent practice-changing trials have highlighted the importance of
polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) in metastatic castrate …

Genome instability has been identified as one of the enabling hallmarks in cancer. DNA
damage response (DDR) network is responsible for maintenance of genome integrity in …

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the
past decade, several new treatments for advanced prostate cancer have been approved …